Has Inflammation a Significant Implication in Lung Cancer Evolution?

Lung Neoplasms Clinical Trial

Official title:

L'Inflammation A-t-elle Une Implication Significative Dans l'évolution du Cancer Bronchique?

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT02484872
• Other study ID #: ELCWP01501
• Status: Active, not recruiting
• Start date: May 2015
• Est. completion date: December 2023

Study information

• Verified date: August 2021
• Source: European Lung Cancer Working Party
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Systemic inflammation is a potential prognostic factor in cancer. Inflammation scores as the Glasgow score have been tested in cancer and specifically in lung cancer patients. The aim of the study is to look at the prognostic and predictive value of inflammation during cancer evolution, on the risk of complications leading to ICU admission and the risk of death.

Description:

Patients with newly diagnosed lung cancer will be eligible. All patients will have a blood sampling allowing testing inflammation and cytokine analyses at diagnosis, during work-up and in case of complication.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 400
• Est. completion date: December 2023
• Est. primary completion date: December 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Lung neoplasms irrespective of stage, histology

Exclusion Criteria:

• Previously treated lung neoplasms

• A history of prior malignant tumour, except non-melanoma skin cancer or in situ carcinoma of the cervix or cured malignant tumour (more than 5 year disease-free interval)

Related Conditions & MeSH terms

• Lung Neoplasms

Locations

Country	Name	City	State
Belgium	Department of Intensive Care Unit and Thoracic Oncology Institut Jules Bordet	Brussels

Sponsors (2)

Lead Sponsor	Collaborator
European Lung Cancer Working Party	Jules Bordet Institute

Country where clinical trial is conducted

Belgium, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Survival		Measured from diagnosis until death or last date known to be alive, or at least 48 months
Secondary	Complications leading to emergency/ICU	Recording any complication leading to consultation at the emergency department or admission into the intensive care unit	From inclusion until death, or a least 48 months